(News Bulletin 247) – Bristol Myers Squibb on Saturday announced four-year follow-up results from the Phase 3 CheckMate -9LA trial demonstrating durable long-term survival benefits with Opdivo (nivolumab) plus Yervoy (ipilimumab) with two chemotherapy cycles in patients with metastatic non-small cell lung cancer.
With a minimum follow-up of 47.9 months, the combination of two immunotherapies continued to improve overall survival with 21% of patients treated with Opdivo plus Yervoy with two cycles of chemotherapy alive compared to 16% of patients treated with chemotherapy alone at four years.
With extended follow-up, the clinically meaningful efficacy benefit was maintained across secondary endpoints and key patient subgroups, with benefits more pronounced among patients with high unmet need.
“The sustained results observed demonstrate the long-lasting benefits of combining dual immunotherapy with limited chemotherapy for patients,” said David P. Carbone, MD, Ph, CheckMate-9LA investigator and director of the Thoracic Oncology Center. at the Ohio State University Global Cancer Center.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
